Talk to Alison
00 1 718 618 48 97
Search inside this page
Top countries
Publishers
All regions
data types
Free Market Research Guides to Download
» Purchase Premium Reports
1-30 of 43 reports
Slimming products? 9% growth in 2009 remained stable in comparison to 2008, but was much lower than the review period current value CAGR of 19%. It appears that this category is close to reaching maturity. ...
High-profile diseases such as SARS and the H1N1 virus are playing a key role in creating greater health- consciousness among Thai people. For a growing number of consumers, health and wellness food and ...
Euromonitor International takes a look at current developments in OTC switching activities, and their implications on the future of consumer health. Euromonitor International's global briefing examines ...
In 2009 OTC obesity only increased by less than 1% in current value terms; compared with 2008 this was a further slowdown. In current value terms sales reached NZ$2.0 million. Xenical by Roche Products ...
OTC obesity posted growth of 4% in current value during 2009, with sales reaching A$31 million. Rising obesity and overweight levels in Australia have received much attention from government agencies and ...
Sales of eye care totalled Euros 1.4 million in 2009, lower performance than the previous year due to the low activity in terms of new product development. More Dutch people are becoming aware of OTC eye ...
Herbal/traditional products registered very good value sales growth in 2009, driven by a continuing rise in demand among Dutch consumers for natural and healthy products. Changes in consumer habits are ...
Orlistat was switched in the Netherlands during 2008, paving the way for the introduction of OTC obesity products. In April 2009, GlaxoSmithKline introduced Alli in the Dutch industry , being the sole ...
Ear care saw renewed efforts to promote these products and gain more penetration during the past two years, signalling sustained growth of 8% in current value terms during 2009. Manufacturers invested ...
Sales of OTC obesity products reached NOK10 million in 2009 following the introduction of the first clinically-approved product in this category. Euromonitor International's OTC Obesity Products in Norway ...
In 2009, OTC obesity sales decreased by 5% in current value terms. The only brand present is Xenical, which was not supported with TV advertising and posters in drugstores and pharmacies in 2009, whilst ...
In 2009, calming and sleeping products registered sales of IRR160bn, representing 16% current value growth over the previous year. However, in constant value terms sales declined 2% in the final year of ...
The main story in OTC obesity was the entrance of Alli by GlaxoSmithKline in 2009. According to trade press, this type of event only occurs every 10 years in the pharmaceuticals industry , the last time ...
2009 saw the launch of Alli within Spain. This is the only OTC obesity product available in Spain. In its first year sales of Alli reached a value of Euros 9 million. Euromonitor International's OTC Obesity ...
2009 saw the launch of the Alli OTC obesity brand across the Germany industry . Previously only available in the USA, Alli experienced a considerable industry ing campaign across Germany, part of which ...
2009 was the first year that OTC obesity gained a presence in Poland. In April 2009 GlaxoSmithKline Pharmaceuticals SA launched the first orlistat-based OTC obesity product under the Alli brand name. 2009 ...
GlaxoSmithKline's Alli was introduced in April 2009, as in all other European countries. The sales for 2009 were estimated at Euros 100,000. This corresponds to a minimum of 520 consumers, assuming an ...
Interest in herbal/traditional products has grown as the emphasis on health and wellness has been increasing. The economic downturn has, however, made consumers more careful with their spending, and they ...
The product category was switched to OTC status in May 2009. There is much public focus on the dangers and growing problem of obesity in Denmark. Consumers therefore showed keen interest in this first ...
Despite the government's 2003 implementation of the Tobacco Regulation Act (RA 9211), which bans smoking in public areas, NRT smoking cessation aids remained a niche segment in the Philippines in 2009. ...
OTC obesity current value sales declined by 10% in 2009 to reach Ps343 million. Volume sales also declined by 10%. During the first half of the review period, demand for OTC obesity products grew strongly ...
Slimming products experienced a significant slowdown in current value sales growth in 2009 as Filipino consumers started to feel the effects of the global financial crisis. Middle-income consumers - the ...
Having enjoyed healthy growth rates during earlier years of the review period, slimming products were among the victims of the economic crisis. Despite being increasingly exposed to social pressure to ...
Value sales of OTC obesity in Portugal, comprised exclusively of the Alli brand, represented Euros 2 million in 2009. In fact, Alli the active ingredient of which is Oristat, was switched to be available ...
OTC obesity observed 1% current value growth to attain S$1 million sales in 2009. There were reports citing possible liver damage when consuming the OTC obesity drug Ecumenical during 2009 whereby consumers ...
Slimming salons continued to have intensive industry ing campaigns to attract consumers. Television variety programmes shown during prime viewing times were sponsored by key slimming salons such as Citispa. ...
With obesity becoming a major concern among affluent urban consumers, and slimming products? sales gaining momentum, more players have sought a share in a industry dominated by direct sellers. Upscale ...
While a ban on smoking in public places came into effect in October 2008, it did not result in an expansion in the availability of NRT smoking cessation aids in India. Despite growing awareness of the ...
Sales of OTC obesity treatments declined by 2% in 2009. The switch of Alli, the first FDA approved weight loss drug, is proving to be a disappointment for GlaxoSmithKline, despite the state of the US population ...
2009 proved to be a very challenging year for the slimming products segment , as weight loss supplements continued to freefall. Dietary supplements barely recovered in 2006 following the ephedra controversy, ...
» Download Public Reports
About 200 reports
... Hormones (rivera et al., 2001).iodine deficiency disorders had been widely recognized as one of the important public health problems especially in developing countries throughout the world. According ...
Reportlinker.com © Copyright 2013. All rights reserved.